Deborah White

Professor, PhD, FFSc(RCPA)

  • Director, Cancer Program, Cancer
  • 4300 Citations
  • 28 h-Index
1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Letter
2019

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

Ross, D. M., Pagani, I., Irani, Y., Clarson, J., Gray, T., Dang, Y., McLean, J., Saunders, V., Carne, L., Reynolds, J., Ritchie, D. S., White, D., Branford, S., Hughes, T. & Yong, A., 1 Aug 2019, In : British Journal of Haematology. 186, 3, p. e56-e60

Research output: Contribution to journalLetter

4 Citations (Scopus)
2017

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment

Heatley, S., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, Y., McClure, B., Venn, N. C., Moore, S., Suttle, J. M., Law, T., Ng, A., Muskovic, W., Norris, M., Revesz, T., Osborn, M., Moore, S., Suppiah, R., Fraser, C., Alvaro, F. & 7 others, Hughes, T., Mullighan, C. G., Marshall, G. M., Dalla Pozza, L., Yeung, D., Sutton, R. & White, D., Dec 2017, In : Haematologica. p. e490-e493

Research output: Contribution to journalLetter

17 Citations (Scopus)
2016

Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL

Trahair, T. N., Lock, R. B., Sutton, R., Sia, K. C. S., Evans, K., Richmond, J., Law, T., Venn, N. C., Irving, J. A., Moore, S., Nievergall, E., Dang, P., Heatley, S. L., White, D. L. & Revesz, T., 1 Sep 2016, In : Bone Marrow Transplantation. 51, 9, p. 1279-1282 4 p.

Research output: Contribution to journalLetter

5 Citations (Scopus)
2015

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

Lu, L., Saunders, V. A., Leclercq, T. M., Hughes, T. P. & White, D. L., 7 Aug 2015, In : Leukemia. 29, 8, p. 1792-1794 3 p.

Research output: Contribution to journalLetter

11 Citations (Scopus)

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment

Yeung, D. T., Moulton, D. J., Heatley, S. L., Nievergall, E., Dang, P., Braley, J., Branford, S., Moore, S., Mullighan, C. G., Hughes, T. P. & White, D. L., 10 Jan 2015, In : Leukemia. 29, 1, p. 230-232 3 p.

Research output: Contribution to journalLetter

16 Citations (Scopus)
2014

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients

Kok, C. H., Leclercq, T., Watkins, D. B., Saunders, V., Wang, J., Hughes, T. P. & White, D. L., 1 Jan 2014, In : Leukemia. 28, 3, p. 702-705 4 p.

Research output: Contribution to journalLetter

5 Citations (Scopus)
2013
21 Citations (Scopus)

Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation

Kok, C. H., Watkins, D. B., Leclercq, T., D'Andrea, R. J., Hughes, T. P. & White, D. L., 1 Jun 2013, In : Leukemia. 27, 6, p. 1427-1430 4 p.

Research output: Contribution to journalLetter

9 Citations (Scopus)

NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis

Watkins, D. B., Hughes, T. P., White, D. L. & D'Andrea, R. J., 1 Feb 2013, In : Leukemia. 27, 2, p. 489-490 2 p.

Research output: Contribution to journalLetter

8 Citations (Scopus)
2010
8 Citations (Scopus)
24 Citations (Scopus)
33 Citations (Scopus)
2007

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs [4]

White, D., Saunders, V., Quinn, S. R., Manley, P. W. & Hughes, T., 15 Apr 2007, In : Blood. 109, 8, p. 3609-3610 2 p.

Research output: Contribution to journalLetter

39 Citations (Scopus)